Inclusion Criteria:

        Phase I part:

        - Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease
        as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite
        standard therapy or are intolerant of standard therapy, or for whom no standard therapy
        exists

        Phase II part:

          -  Patients with advanced/metastatic solid tumors, with at least one measurable lesion as
             determined by RECIST version 1.1, who have had disease progression following their
             last prior therapy and fit into one of the following groups:

          -  Group 1: NSCLC

          -  Group 2: Melanoma

          -  Group 3: Renal cancer

          -  Group 4: Mesothelioma

          -  Group 5: TNBC

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1

          -  Patient must have a site of disease amenable to biopsy, and be a candidate for tumor
             biopsy.

        Exclusion Criteria:

          -  History of severe hypersensitivity reactions to study treatment ingredients or other
             mAbs

          -  Active, known or suspected autoimmune disease

          -  Active infection requiring systemic antibiotic therapy

          -  HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Patients receiving chronic treatment with systemic steroid therapy, other than
             replacement-dose corticosteroids in the setting of adrenal insufficiency

          -  Patients receiving systemic treatment with any immunosuppressive medication

          -  Use of live vaccines against infectious disease within 4 weeks of initiation of study
             treatment

          -  Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.

          -  Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that
             require local CNS-directed therapy or increasing doses of corticosteroids within the
             prior 2 weeks

          -  History of drug-induced pneumonitis or current pneumonitis.